SCHEMBL3602293

SCHEMBL3602293

[NH]c1ccc2c(c1)CC(N1CCC(=O)CC1)C(=O)N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.34
KMT2A Q03164 4/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 2/20 0.33
GAA P10253 2/20 0.33
TSHR P16473 1/20 0.33
APEX1 P27695 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTR2C P28335 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CRBN Q96SW2 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
PARP1 P09874 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602308 0.89 DRD2 (0.41) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3580789 0.88 TSHR (0.46) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL4457511 0.86 DRD2 (0.44) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3596527 0.86 DRD2 (0.46) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3601998 0.85 DRD2 (0.43) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3606189 0.85 DRD2 (0.43) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3595288 0.84 DRD2 (0.42) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3604332 0.84 DRD2 (0.42) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3602300 0.84 DRD2 (0.44) DRD2DRD4ALDH1A1LMNAHTT
SCHEMBL3591371 0.81 DRD2 (0.40) DRD2DRD4ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 DRD2 530/4885DRD4 795/4885ALDH1A1 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.